fingolimod hydrochloride has been researched along with Armstrong Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bevan, MJ; Fink, PJ | 1 |
| Altman, JD; Moseley, NB; Premenko-Lanier, M; Pruett, ST; Romagnoli, PA | 1 |
| Marsolais, D; Oldstone, MB; Rosen, H; Walsh, KB; Welch, MJ | 1 |
3 other study(ies) available for fingolimod hydrochloride and Armstrong Syndrome
| Article | Year |
|---|---|
Immunology: Surprising side effects.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Mice; Propylene Glycols; Sphingosine | 2008 |
Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection.
Topics: Animals; Chronic Disease; Fingolimod Hydrochloride; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2008 |
Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.
Topics: Animals; Antiviral Agents; beta-Alanine; Fingolimod Hydrochloride; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Lymphopenia; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Thiophenes; Treatment Outcome | 2010 |